26 September 2020>: Articles
SARS-CoV-2 Infection and COVID-19 in 5 Patients in Ecuador After Prior Treatment with Hydroxychloroquine for Systemic Lupus Erythematosus
Unusual clinical course, Diagnostic / therapeutic accidents, Unusual setting of medical care, Adverse events of drug therapy, Educational Purpose (only if useful for a systematic review or synthesis)
María Fernanda Zurita B , Adriana Iglesias Arreaga B* , Adriana A Luzuriaga Chavez F , Luis Zurita ADOI: 10.12659/AJCR.927304
Am J Case Rep 2020; 21:e927304
Table 1. Demographic and treatment information for lupus patients with COVID-19.
Characteristics | n=5 (%) |
---|---|
34.4 | |
8 | |
Male | 0 (0) |
Female | 5 (100) |
Arterial hypertension | 1 (20) |
Chronic obstructive pulmonary disease | 0 (0) |
Type 2 DM | 0 (0) |
Nervous system disease | 0 (0) |
Kidney disease | 0 (0) |
Hydroxychloroquine 200 mg/day | 5 (100) |
Azithromycin 500 mg/day | 4 (80) |
Tocilizumab 400 mg/day | 1 (20) |
Corticosteroids 20 mg/day | 2 (40) |
Ivermectin 12 mg/day | 0 (0) |
Low weight molecular heparin 40 mg/day | 1 (20) |
Type 2 DM – type 2 diabetes mellitus. |